Integra LifeSciences (NASDAQ:IART) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings results on Monday. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.01, Briefing.com reports. Integra LifeSciences had a return on equity of 13.95% and a net margin of 1.51%. The firm had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same period in the previous year, the company posted $0.71 earnings per share. The company’s quarterly revenue was up 9.7% compared to the same quarter last year.

Integra LifeSciences Stock Down 1.5 %

NASDAQ:IART opened at $25.03 on Wednesday. The stock’s fifty day moving average price is $29.67 and its two-hundred day moving average price is $33.52. Integra LifeSciences has a 52-week low of $22.36 and a 52-week high of $46.09. The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.35 and a current ratio of 4.68. The company has a market cap of $1.97 billion, a price-to-earnings ratio of 50.06, a P/E/G ratio of 1.12 and a beta of 1.11.

Insiders Place Their Bets

In other news, Chairman Stuart Essig acquired 52,641 shares of Integra LifeSciences stock in a transaction on Thursday, May 23rd. The shares were purchased at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares in the company, valued at $13,900,897.78. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 3.10% of the company’s stock.

Analyst Ratings Changes

IART has been the topic of several analyst reports. Wells Fargo & Company lowered Integra LifeSciences from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $45.00 to $25.00 in a research note on Tuesday, May 7th. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Bank of America reduced their target price on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a report on Tuesday, May 7th. Oppenheimer downgraded Integra LifeSciences from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 7th. Finally, Truist Financial reduced their target price on Integra LifeSciences from $32.00 to $26.00 and set a “hold” rating on the stock in a report on Tuesday. Four analysts have rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $29.25.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.